Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PD-L1 t-haNK Clear all
Recruiting Phase 2 Interventional

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

NCT06161545
View directory record Official record
Conditions
Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
Interventions
PD-L1 t-haNK cells, pembrolizumab, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 18, 2026, 1:13 AM EDT
Completed Phase 2 Interventional

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

NCT04847466
View directory record Official record
Conditions
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
Interventions
N-803, Pembrolizumab, PD-L1 t-haNK
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 18, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
PD-L1 t-haNK, Cetuximab, NAI
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 18, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03329248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 18, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03387098
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 18, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884
View directory record Official record
Conditions
Advanced Triple Negative Breast Cancer
Interventions
N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 18, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

NCT04050709
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Interventions
PD-L1 t-haNK
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

NCT03387111
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 18, 2026, 1:13 AM EDT
Recruiting Phase 1 Interventional

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

NCT05618925
View directory record Official record
Conditions
Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions
N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newport Beach, California • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

NCT06061809
View directory record Official record
Conditions
Glioblastoma
Interventions
Bevacizumab, PD-L1 t-haNK, N-803, Tumor Treating Fields (TTFields, 200 kHz)
Drug · Device
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
El Segundo, California • Fullerton, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 18, 2026, 1:13 AM EDT